Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Emerging Outsourcing Destinations: Pharmas Strategies and Growth Drivers
JZMed

Jim Zhang, President, JZMed

Abstract
Emerging markets have been recognized as the key growth driver of the global pharmaceutical market.  They have thus received increasing attention from almost all drug companies around the world.  In addition to the attraction of the fast growing pharmaceutical market, the availability of a variety of outsourcing services at relatively low cost with increasing service capability and improved quality, is also attracting drug companies from all over the world to look for the outsourcing or collaboration opportunities in these countries, in particular China and India.  Currently, a large number of drug companies from all over the world are aggressively looking for partnerships with local companies or research organizations.  Meanwhile, to meet the high demand by the global drug companies and to position them well in these fast growing pharma outsourcing markets, almost all world major CROs and CMOs have made significant investments in these emerging countries.  This presentation will discuss in detail a series of new outsourcing strategies currently pursued by the global drug companies in these key emerging outsourcing countries and the strengths and weakness of the local service providers.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Paramedics May be First Line of Treatment for Stroke
NIH study demonstrates feasibility of getting drugs to stroke patients faster.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Early Blood Glucose Control Lengthens Life in People with Type 1 Diabetes
Reductions in diabetes complications resulting from tight glucose control translate into longer lifespans.
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters